AYTU
Aytu BioPharma Inc. · NASDAQ
- Market cap
- $19.8M
Aytu BioPharma Inc. (AYTU) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 12 wire items for AYTU, including 6 SEC filings, 3 market updates and 1 press release or news item. The most recent was published Nov 17, 2026.
Financial highlights
Full financials- Revenue, TTM
- $58.52M
- Revenue growth
- -8.1%
- Net income, TTM
- -$20.10M
- Net margin
- -34.3%
- Cash
- $25.49M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks27+1000%
2026-05-242026-11-15
Mix1690d
- SEC Filings8(50%)
- Market5(31%)
- Other1(6%)
- M&A1(6%)
- Analyst1(6%)
Activity · 52 weeks4725 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- ANALYSTAytu BioScience downgraded by Lake Street with a new price targetLake Street downgraded Aytu BioScience from Buy to Hold and set a new price target of $2.70
- SECSEC Form 10-Q filed by Aytu BioPharma Inc.10-Q - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECSEC Form 425 filed by Aytu BioPharma Inc.425 - AYTU BIOPHARMA, INC (0001385818) (Subject)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
- NEWSAytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial ResultsDue to the pending merger with Rosemont Pharmaceuticals Holdings, Inc., the Company will not be holding an earnings conference call to discuss its financial results DENVER, CO / ACCESS Newswire / November 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2027 first quarter ended September 30, 2026.Q1 Fiscal 2027 HighlightsNet revenue increased 6.9% to $14.8 million versus $13.9 million in Q1 fiscal 2026.EXXUA net revenue was $4.9 million, up 24.5
- PRRosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansionAgreement to acquire Aytu BioPharma for all-cash consideration of $2.70 per Aytu share.Proposed acquisition brings an established ADHD portfolio and an emerging Major Depressive Disorder (MDD) asset alongside a US commercial platform.Closing anticipated to occur in late December 2026, subject to the satisfaction or waiver of the conditions in the tender offer. GREENVILLE, S.C. and LEEDS, United Kingdom, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rosemont Pharmaceuticals Holdings, Inc. ("Rosemont"), a global specialty pharmaceutical company focused on designing and delivering medicines around patients’ needs, today announced that it has entered into a definitive merger agreement to acquire Aytu B
- SECAytu BioPharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
- NEWSRosemont Pharmaceuticals to Acquire Aytu BioPharma in All-Cash Tender OfferAgreement with Rosemont Pharmaceuticals provides for all-cash consideration of $2.70 per shareTender offer price represents 41.1% premium to 30-day volume-weighted average price and 51.7% premium to the closing price on November 13, 2026Tender offer support agreements secured from Nantahala Capital Management, Stonepine Capital Management and Aytu's directors and officersClosing is anticipated to occur by the end of calendar year 2026, subject to the satisfaction or waiver of the conditions to the tender offer DENVER, CO / ACCESS Newswire / November 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicine
- NEWSAytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026DENVER, CO / ACCESS Newswire / November 10, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2027 first quarter after the market close on Monday, November 16, 2026. The Company has scheduled a conference call and webcast that same day, Monday, November 16, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Monday, November 16, 2026, at 4:30 p.m. Eastern time.Call-in Inform
- FDAFDA Approval for ZOLPIMIST issued to AYTUSubmission status for AYTU's drug ZOLPIMIST (SUPPL-13) with active ingredient ZOLPIDEM TARTRATE has changed to 'Approval' on 11/09/2026. Application Category: NDA, Application Number: 022196, Application Classification: Labeling
- SECSEC Form DEFA14A filed by Aytu BioPharma Inc.DEFA14A - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECSEC Form DEF 14A filed by Aytu BioPharma Inc.DEF 14A - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECSEC Form 10-K filed by Aytu BioPharma Inc.10-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- SECAytu BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AYTU BIOPHARMA, INC (0001385818) (Filer)
- NEWSAytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial ResultsFourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarterFourth quarter fiscal 2026 Adjusted EBITDA of $0.5 millionEXXUA net revenue of $6.6 million in fiscal 2026, including $3.9 million in the fourth quarter, following full commercial launch during third quarter fiscal 2026EXXUA fourth quarter fiscal 2026 total prescriptions were 3,323, up approximately 138% from 1,398 in third quarter fiscal 2026$26.3 million cash balance at June 30, 2026Company to host conference call and webcast today, September 22, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / September 22, 2026 / Aytu BioPharma, Inc. (the "Company" or "Ay
- NEWSAytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 2026, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Conference Call DetailsDate and Time: Tuesday, September 22, 2026, at 4:30 p.m. East
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.SCHEDULE 13G/A - AYTU BIOPHARMA, INC (0001385818) (Subject)
- INSIDERChief Commercial Officer Pyszczymuka Greg was granted 20,000 shares, increasing direct ownership by 55% to 56,102 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERChief Executive Officer Disbrow Joshua R. was granted 30,000 shares, increasing direct ownership by 14% to 237,203 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERChief Business Officer Disbrow Jarrett was granted 15,000 shares, increasing direct ownership by 24% to 76,568 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERChief Financial Officer Selhorn Ryan J was granted 25,000 shares, increasing direct ownership by 50% to 74,743 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Liu Vivian H was granted 10,000 shares, increasing direct ownership by 50% to 29,825 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Jain Abhinav was granted 10,000 shares, increasing direct ownership by 51% to 29,500 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Dockery Carl was granted 10,000 shares, increasing direct ownership by 47% to 31,152 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
- INSIDERDirector Donofrio John Jr. was granted 10,000 shares, increasing direct ownership by 73% to 23,762 units (SEC Form 4)4 - AYTU BIOPHARMA, INC (0001385818) (Issuer)
AYTU FAQ
10 questionsWhat does Aytu BioPharma Inc. do?
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal...What is the latest news on AYTU?
In the last 30 days Quantisnow tracked 12 wire items for AYTU: 6 SEC filings, 3 market updates, 1 press release or news item and 1 M&A update. The most recent was published on November 17, 2026.What is AYTU revenue?
Aytu BioPharma Inc. (AYTU) reported $58.52M of revenue for the twelve months ended Sep 30, 2026. That is down 8.1% from the year before. Revenue for fiscal 2026 was $57.57M.Is AYTU profitable?
No. Aytu BioPharma Inc. reported a net loss of $20.10M for the twelve months ended Sep 30, 2026.How much cash and debt does AYTU have?
Aytu BioPharma Inc. reported $25.49M in cash and cash equivalents and $10.51M of debt on its most recent balance sheet in SEC filings.Where does AYTU stock trade?
Aytu BioPharma Inc. (AYTU) is listed on NASDAQ.What sector and industry is AYTU in?
Aytu BioPharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AYTU?
Across the last 3 analyst actions on Aytu BioPharma Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Lake Street: Hold with a $2.70 price target on 2026-11-17. Recent price targets range from $2.70 to $12.00.What companies are similar to AYTU?
Notable peers in the same industry include ZVRA (Zevra Therapeutics Inc.), SUPN (Supernus Inc.), ETON (Eton Pharmaceuticals Inc.), COLL (Collegium Pharmaceutical Inc.), HRMY (Harmony Biosciences Holdings Inc.). Compare AYTU side-by-side with any of them on Quantisnow.How can I track AYTU on Quantisnow?
Quantisnow aggregates Aytu BioPharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AYTU to receive live email and push alerts on every new disclosure.